Where do things stand now with personalizing myeloma therapy to a patients genetic profile? At the American Society of Hematology (ASH) 2017 conference in Atlanta, Esther Schorr speaks with Dr. Gareth Morgan, Director of the UAMS Myeloma Institute, about new oncogenes in myeloma. They also discuss the importance of testing at the time of myeloma diagnosis to set a treatment plan. Watch for this top myeloma experts take on the latest myeloma research.
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a PatientÂ’s Myeloma?
